Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) | WebDisclosure

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Headlines Articles Press releases Aspire Biopharma Holdings, Inc.

Home
Companies
Aspire Biopharma Holdings, Inc.

BRIEF

published on 12/04/2025 at 15:05, 16 hours 20 minutes ago

Aspire Biopharma publie ses résultats d'activité pour le troisième trimestre 2025

Soumission À La FDA Technologie Sublinguale Aspire Biopharma BUZZ BOMB™ Mise À Jour Du Troisième Trimestre 2025
BRIEF

published on 12/04/2025 at 15:05, 16 hours 20 minutes ago

Aspire Biopharma Reports Q3 2025 Business Developments

FDA Submission Sublingual Technology Aspire Biopharma BUZZ BOMB™ Q3 2025 Update
PRESS RELEASE

published on 12/04/2025 at 15:00, 16 hours 25 minutes ago

Aspire Biopharma Provides Q3 2025 Business Update
Aspire Biopharma updates Q3 2025 progress, including FDA submission, patent application, and BUZZ BOMB™ launch. Anticipates NDA for sublingual aspirin in H1 2026

Patent Application FDA Submission Aspire Biopharma BUZZ BOMB™ Launch NDA 2026
BRIEF

published on 12/02/2025 at 15:05, 2 days 16 hours ago

Aspire Biopharma fait progresser les discussions avec la FDA concernant l'aspirine sublinguale

Soumission À La FDA Résultats Des Essais Cliniques Aspire Biopharma Aspirine Sublinguale Traitement De La Crise Cardiaque
BRIEF

published on 12/02/2025 at 15:05, 2 days 16 hours ago

Aspire Biopharma Advances FDA Discussions for Sublingual Aspirin

FDA Submission Clinical Trial Results Aspire Biopharma Sublingual Aspirin Heart Attack Treatment
PRESS RELEASE

published on 12/02/2025 at 15:00, 2 days 16 hours ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval

Clinical Trial FDA Submission Aspire Biopharma Sublingual Aspirin Acute Myocardial Infarction
BRIEF

published on 11/26/2025 at 15:05, 8 days 16 hours ago

Aspire Biopharma Strengthens Team with New Appointment

Sublingual Delivery Aspire Biopharma Dr. Mark J. Jaroszeski DNA/drug Innovation Scientific Team
BRIEF

published on 11/26/2025 at 15:05, 8 days 16 hours ago

Aspire Biopharma renforce son équipe avec une nouvelle nomination

Administration Sublinguale Aspire Biopharma Dr Mark J. Jaroszeski Innovation ADN/médicament Équipe Scientifique
PRESS RELEASE

published on 11/26/2025 at 15:00, 8 days 16 hours ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Aspire Biopharma appoints Dr. Mark J. Jaroszeski, PhD as a key addition to its scientific team, enhancing drug delivery technology development and innovation

Drug Delivery Technology Sublingual Delivery Aspire Biopharma Mark J. Jaroszeski Medical Engineering
BRIEF

published on 11/06/2025 at 15:05, 28 days 16 hours ago

Aspire Biopharma entame des discussions de partenariat au CPHI de Francfort

Technologie D'administration De Médicaments Partenariats Pharmaceutiques Aspire Biopharma Aspirine Sublinguale CPHI Francfort

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 24 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 34 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 10 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:14, 13 hours 10 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 25 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 40 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE